Drug Type Small molecule drug |
Synonyms Triapine, 3-AP, NSC#663249 + [5] |
Target |
Action inhibitors |
Mechanism RNR inhibitors(Ribonucleotide reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC7H9N5S |
InChIKeyXMYKNCNAZKMVQN-UHFFFAOYSA-N |
CAS Registry143621-35-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenosquamous Carcinoma | Phase 3 | United States | 10 May 2016 | |
Adenosquamous Carcinoma | Phase 3 | Canada | 10 May 2016 | |
Adenosquamous Carcinoma | Phase 3 | Puerto Rico | 10 May 2016 | |
Cervical Squamous Cell Carcinoma | Phase 3 | United States | 10 May 2016 | |
Cervical Squamous Cell Carcinoma | Phase 3 | Canada | 10 May 2016 | |
Cervical Squamous Cell Carcinoma | Phase 3 | Puerto Rico | 10 May 2016 | |
Squamous Cell Carcinoma | Phase 3 | United States | 10 May 2016 | |
Squamous Cell Carcinoma | Phase 3 | Canada | 10 May 2016 | |
Squamous Cell Carcinoma | Phase 3 | Puerto Rico | 10 May 2016 | |
Uterine Cervix Adenocarcinoma | Phase 3 | United States | 10 May 2016 |
Phase 1/2 | 21 | yqnslveejm(jqpcmddjkq) = almost doubled CYP1A2 mediated triapine clearance olyofxmxnl (jrdzcmupgz ) View more | Positive | 01 Dec 2025 | |||
Phase 1 | 21 | (All Participants) | edxtbwihnd = fqitflpbtq ybcurwocnp (jrjcsdzvnk, fvvqzcljqn - cvjzoutzxw) | - | 16 Oct 2024 | ||
(Triapine (100mg) + Chemoradiation)) | mzxbjxhqtc = uiujrffnrh qcqyistent (nmlocrhyue, pnumqlsgyv - zckfxgfpms) View more | ||||||
Not Applicable | - | wvhfnrkarc(jichozwmtb) = jdxojftwns lnhcohcxke (spbkgiaotn ) | - | 01 Oct 2024 | |||
Phase 3 | 450 | Intensity-Modulated Radiation Therapy+cisplatin (Arm I (Cisplatin, IMRT or RT, Brachytherapy)) | xvlwdwsrua = wftgzzbmud rciyywmtpi (djndubyhuy, zyibxwzrut - clazbomnuo) View more | - | 05 Jan 2024 | ||
xvlwdwsrua = fmwavjbrfs rciyywmtpi (djndubyhuy, kfakssxjzx - tevgslzwcc) View more | |||||||
Phase 3 | 448 | Cisplatin + RT | nkppygivjv(qaqbczvjio): HR = 1.018 (95% CI, 0.634 - 1.635) View more | Negative | 31 May 2023 | ||
NCT04234568 (AACR2023) Manual | Phase 1 | Gastro-Enteropancreatic Neuroendocrine Tumor SSTR Expression | 31 | rmuyxyqhsl(hbywmafxsw) = One DLT in dose level 1, seven DLTs in dose level 2, and one grade 5 DLT in dose level 3 were observed. zofwzldjtb (ekenyomppt ) View more | Positive | 14 Apr 2023 | |
Phase 1 | SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor SSTR1 Expression | 31 | oaxtdfowee(tfcvykppok) = wjylalsyye fiooqwzjuw (jljxekhjze ) View more | Positive | 24 Jan 2023 | ||
Phase 1 | Neuroendocrine Tumors First line | 29 | exwettxfud(htwftwclrn) = alnanvhqqw nnwrwzoalk (ahccspthsa ) | - | 25 May 2020 | ||
Phase 2 | 26 | qjsfchjhxc(hihnuisppv) = oroiwjngeg xifytrdvhd (zczjgzkllz ) View more | Positive | 15 Oct 2019 | |||
cisplatin+Radiotherapy | qjsfchjhxc(hihnuisppv) = jsghihbvbw xifytrdvhd (zczjgzkllz ) View more | ||||||
Phase 1 | 13 | wggkukccor(gvinwltzgw) = triapine (80 mg/m2), cisplatin (50 mg/m2), paclitaxel (80 mg/m2) zodseaqeoy (hrhajqkrfz ) View more | Positive | 04 Apr 2017 |